JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2000; 36:2072-2080
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groenning, B. A.
Right arrow Articles by Hildebrandt, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groenning, B. A.
Right arrow Articles by Hildebrandt, P. R.

Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure

Bjoern A. Groenning, MD* {dagger}, Jens C. Nilsson, MD*, Lars Sondergaard, MD* {dagger}, Thomas Fritz-Hansen, MD*, Henrik B. W. Larsson, MD, DMSc* and Per R. Hildebrandt, MD, DMSc{dagger}

* Danish Research Center of Magnetic Resonance, Department of Magnetic Resonance, H:S Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark
{dagger} Department of Cardiology and Endocrinology, H:S Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark



View larger version (12K):

[in a new window]
 
Figure 1 LVEDVI over time. Mean LVEDVI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and six months after randomization. *The metoprolol CR/XL group versus the placebo group. CI = confidence interval; LVEDVI = left ventricular end-diastolic volume index.

 


View larger version (12K):

[in a new window]
 
Figure 2 LVESVI over time. Mean LVESVI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and six months after randomization. *The metoprolol CR/XL group versus the placebo group. CI = confidence interval; LVESVI = left ventricular end-systolic volume index.

 


View larger version (12K):

[in a new window]
 
Figure 3 LVEF over time. Mean LVEF is shown in the metoprolol CR/XL group and in the placebo group at baseline, 5 or 7 weeks and six months after randomization. *The metoprolol CR/XL group versus the placebo group. CI = confidence interval; LVEF = left ventricular ejection fraction.

 


View larger version (12K):

[in a new window]
 
Figure 4 LVmassI over time. Mean LVmassI is shown in the metoprolol CR/XL group and in the placebo group at baseline, five or seven weeks and six months after randomization. *The metoprolol CR/XL group versus the placebo group. Metoprolol CR/XL group versus baseline: p = 0.01; placebo group versus baseline: p = 0.005. CI = confidence interval; LVmassI = left ventricular mass index.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2000 by the American College of Cardiology Foundation.